Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).
Exposing hiding lymphoma cells to immune system miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.